Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-93.46	-87.87	-78.06	-68.26	-43.59	-21.44
Depreciation & Amortization	5.16	5.32	5.41	4.21	1.73	0.39
Stock-Based Compensation	10.52	11.85	16.2	6.92	1.96	0.38
Other Adjustments	3.81	3.9	7.04	-7.85	0.14	-1.32
Change in Receivables	0.87	0.95	1.19	-2.45	-	-
Changes in Accounts Payable	-0.12	1.05	-1.11	-0.08	0.72	0.7
Changes in Accrued Expenses	1.72	-1.64	-0.89	1.63	4.53	1.85
Changes in Income Taxes Payable	-	-	-3.27	1.73	1.54	-
Changes in Unearned Revenue	-11.17	-21.1	-46.8	-30.3	65.66	44.23
Changes in Other Operating Activities	-3.46	-1.36	-8.79	3.04	-2.96	-0.52
Operating Cash Flow	-85.49	-88.89	-109.07	-91.41	29.72	24.26
Operating Cash Flow Growth	-	-	-	-	22.54%	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-0.31	-0.57	-3.11	-9.81	-13.98	-2.9
Sale of Property, Plant & Equipment	-	0.04	-	-	-	-
Purchases of Investments	-66.27	-66.41	-306.42	-208.1	-214.85	-71.41
Proceeds from Sale of Investments	163.46	170.47	221.38	263.64	106.63	-
Investing Cash Flow	96.88	103.53	-88.16	45.73	-122.2	-74.32

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Issuance of Common Stock	0.17	0.2	84.01	-	-	-
Net Common Stock Issued (Repurchased)	0.17	0.2	84.01	-	-	-
Issuance of Preferred Stock	-	-	-	4.3	239.59	9.95
Net Preferred Stock Issued (Repurchased)	-	-	-	4.3	239.59	9.95
Other Financing Activities	-0.24	-0.56	-	-3.28	-	29.97
Financing Cash Flow	-0.07	-0.36	84.01	1.01	239.59	39.92

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Cash Flow	11.32	14.28	-113.22	-44.66	147.12	-10.14

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-85.8	-89.47	-112.19	-101.22	15.75	21.35
Free Cash Flow Growth	-	-	-	-	-26.26%	-
FCF Margin	-632.67%	-354.88%	-214.53%	-226.17%	91.55%	8787.65%
Free Cash Flow Per Share	-2.29	-2.40	-3.40	-29.73	4.63	6.27
Levered Free Cash Flow	-101.64	-106.17	-136.63	-97.84	13.65	22.3
Unlevered Free Cash Flow	-108.54	-114.25	-141.61	-118.54	9.81	19.79

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Aug 10, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 13, 2026

Data Sources Report a data error